Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis

Michael D Wiese; Matthew Schnabl; Catherine O'Doherty; Llewellyn D Spargo; Michael J Sorich; Leslie G Cleland; Susanna M Proudman

doi:10.1186/ar3911

Download references

Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis

Michael D Wiese^*^†, Matthew Schnabl^†, Catherine O'Doherty, Llewellyn D Spargo, Michael J Sorich, Leslie G Cleland and Susanna M Proudman

* Corresponding author: Michael D Wiese michael.wiese@unisa.edu.au
† Equal contributors

Arthritis Research & Therapy 2012, 14:R163 doi:10.1186/ar3911

Include	Article citation and all cited references Cited references only Article citation only
Format	EndNote, Zotero or Papers Reference Manager Refworks BibTeX

Arthritis Research & Therapy

Viewing options

Associated material

Tools

Share this article

Download references

Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis

Arthritis Research & Therapy

Viewing options

Associated material

Related literature

Cited by

Other articles by authors

Related articles/pages

Tools

Share this article

Download references

Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis